The CTLA4 inhibitor – now given the brand name Imjudo – is only the second drug in the class to be ... for the application to six months. In the HIMALAYA trial, patients treated with the ...

Herbal Medicinal Products Market. The global herbal medicinal products market is experiencing significant growth, with total ...

The EU recommendation comes shortly after both indications were approved in the US, based on the results of the HIMALAYA and POSEIDON ... Imjudo is only the second drug in the class to be backed ...

23andMe ended an audacious bet it made nearly a decade ago — that it could use the genetic data it had collected not only to assist drug companies but to become one itself. “We are taking ...

From there, we embarked on a slow journey up into the Himalaya. Soon the smooth tarmac roads disappeared, and we needed a 4x4 to navigate the rough tracks that wound their way into the mountains.

Using drugs changes a person's brain structure and functioning, particularly in areas involved in reward, stress, and self-control. These alterations make it harder for people to stop using substances ...

The 13-count federal grand jury indictment charges the company with multiple offenses, including conspiracy to manufacture and distribute fentanyl and the introduction of misbranded drugs into int ...

Godavari Drugs Limited is an India-based company, which is engaged in the business of manufacturing of active pharmaceutical ingredients (API) and its intermediates. The Company is engaged in the ...

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, ...